

Contents

I Diagnosis and Treatment: General Principles		
1 A Clinical Approach to Inherited Metabolic Diseases	3	
<i>Jean-Marie Saudubray, Isabelle Desguerre, Frédéric Sedel, Christiane Charpentier</i>		
Introduction	5	
1.1 Classification of Inborn Errors of Metabolism	5	
1.1.1 Pathophysiology	5	
1.1.2 Clinical Presentation	6	
1.2 Acute Symptoms in the Neonatal Period and Early Infancy (<1 Year)	6	
1.2.1 Clinical Presentations	6	
1.2.2 Metabolic Derangements and Diagnostic Tests	10	
1.3 Later Onset Acute and Recurrent Attacks (Late Infancy and Beyond)	11	
1.3.1 Clinical Presentations	11	
1.3.2 Metabolic Derangements and Diagnostic Tests	19	
1.4 Chronic and Progressive General Symptoms/Signs	24	
1.4.1 Gastrointestinal Symptoms	24	
1.4.2 Muscle Symptoms	26	
1.4.3 Neurological Symptoms	26	
1.4.4 Specific Associated Neurological Abnormalities	33	
1.5 Specific Organ Symptoms	39	
1.5.1 Cardiology	39	
1.5.2 Dermatology	39	
1.5.3 Dysmorphology	41	
1.5.4 Endocrinology	41	
1.5.5 Gastroenterology	42	
1.5.6 Hematology	42	
1.5.7 Hepatology	43	
1.5.8 Immune System	44	
1.5.9 Myology	44	
1.5.10 Nephrology	45	
1.5.11 Neurology	45	
1.5.12 Ophthalmology	45	
1.5.13 Osteology	46	
1.5.14 Pneumology	46	
1.5.15 Psychiatry	47	
1.5.16 Rheumatology	47	
1.5.17 Stomatology	47	
1.5.18 Vascular Symptoms	47	
References	47	
2 Newborn Screening for Inborn Errors of Metabolism	49	
<i>Bridget Wilcken</i>		
2.1 Introduction	51	
2.2 General Aspects of Newborn Screening	51	
2.2.1 Aims and Criteria	51	
2.2.2 Sensitivity, Specificity, and Positive Predictive Value	51	
2.2.3 Technical Aspects of Newborn Screening Tests	51	
2.2.4 Range of Possibilities from Early Detection	52	
2.2.5 Tandem Mass Spectrometry	52	
2.3 Screening for Individual Inborn Errors of Metabolism	53	
2.3.1 Phenylketonuria	53	
2.3.2 Galactosaemias	54	
2.3.3 Aminoacidopathies	54	
2.3.4 Organic Acid Disorders	55	
2.3.5 Fatty Acid Oxidation Disorders	55	
2.3.6 Other Neonatal Screening Programmes	57	
References	57	
3 Diagnostic Procedures: Function Tests and Postmortem Protocol	59	
<i>Guy Touati, Jan Huber, Jean-Marie Saudubray</i>		
3.1 Introduction	61	
3.2 Functional Tests	61	
3.2.1 Metabolic Profile over the Course of the Day	61	
3.2.2 Fasting Test	62	
3.2.3 Glucose Loading Test	65	
3.2.4 Galactose Loading Test	65	
3.2.5 Fructose Loading Test	65	
3.2.6 Protein and Allopurinol Loading Test	66	
3.2.7 Fat Loading Test	66	
3.2.8 Tetrahydrobiopterin Test	66	
3.2.9 Exercise Test	67	
3.3 Postmortem Protocol	68	
3.3.1 Cells and Tissues for Enzyme Assays	68	
3.3.2 Cells and Tissues for Chromosome and DNA Investigations	68	
3.3.3 Skin Fibroblasts	68	
3.3.4 Body Fluids for Chemical Investigations	68	
3.3.5 Imaging	68	
3.3.6 Autopsy	69	
References	69	
4 Emergency Treatments	71	
<i>Viola Prietsch, Hélène Ogier de Baulny, Jean-Marie Saudubray</i>		
4.1 General Principles	73	
4.1.1 Supportive Care	73	

4.1.2	Nutrition	73
4.1.3	Specific Therapies	73
4.1.4	Extracorporeal Procedures for Toxin Removal	73
4.2	Emergency Management of Particular Clinical Presentations	74
4.2.1	Neurological Deterioration	74
4.2.2	Liver Failure	77
4.2.3	Neonatal Hypoglycemia	77
4.2.4	Cardiac Failure	78
4.2.5	Primary Hyperlactatemia	78
4.2.6	Intractable Convulsions	78
4.3	Final Considerations	78
	References	78
5	Treatment: Present Status and New Trends	81
	<i>John H. Walter, J. Ed Wraith</i>	
5.1	Introduction	83
5.2	Reducing the Load on the Affected Pathway	83
5.2.1	Substrate Reduction by Dietary Restriction	83
5.2.2	Substrate Reduction by Inhibition of Enzymes Within the Pathway	83
5.3	Correcting Product Deficiency	84
5.3.1	Replenishing Depleted Products	84
5.3.2	Increasing Substrate Supply	84
5.3.3	Providing Alternative Substrates	85
5.4	Decreasing Metabolite Toxicity	85
5.4.1	Removing Toxic Metabolites	85
5.4.2	Blocking the Effects of Toxic Metabolites	85
5.5	Stimulating Residual Enzyme	85
5.5.1	Co-Enzyme Treatment	85
5.5.2	Enzyme Enhancement Therapy	86
5.6	Transplantation	87
5.6.1	Hematopoietic Stem Cell Transfer	87
5.6.2	Other Organ Transplantation	87
5.7	Pharmacologic Enzyme Replacement	88
5.7.1	Gaucher Disease	88
5.7.2	Fabry Disease	88
5.7.3	Mucopolysaccharidosis Type I	88
5.7.4	Mucopolysaccharidosis Type VI	88
5.7.5	Pompe Disease	88
5.7.6	Other Disorders	88
5.8	Gene Therapy	89
5.8.1	Gene Transfer	89
5.8.2	Pharmacological Gene Therapy	89
5.9	Conclusions	89
	References	96

II Disorders of Carbohydrate Metabolism

6	The Glycogen Storage Diseases and Related Disorders	101
	<i>G. Peter A. Smit, Jan Peter Rake, Hasan O. Akman, Salvatore DiMauro</i>	
6.1	The Liver Glycogenoses	103
6.1.1	Glycogen Storage Disease Type I (Glucose-6-Phosphatase or Translocase Deficiency)	103
6.1.2	Glycogen Storage Disease Type III (Debranching Enzyme Deficiency)	108
6.1.3	Glycogen Storage Disease Type IV (Branching Enzyme Deficiency)	109
6.1.4	Glycogen Storage Disease Type VI (Glycogen Phosphorylase Deficiency)	111
6.1.5	Glycogen Storage Disease Type IX (Phosphorylase Kinase Deficiency)	111
6.1.6	Glycogen Storage Disease Type 0 (Glycogen Synthase Deficiency)	112
6.2	The Muscle Glycogenoses	112
6.2.1	Glycogen Storage Disease Type V (Myophosphorylase Deficiency)	113
6.2.2	Glycogen Storage Disease Type VII (Phosphofructokinase Deficiency)	113
6.2.3	Phosphoglycerate Kinase Deficiency	114
6.2.4	Glycogen Storage Disease Type X (Phosphoglycerate Mutase Deficiency)	114
6.2.5	Glycogen Storage Disease Type XII (Aldolase A Deficiency)	114
6.2.6	Glycogen Storage Disease Type XIII (β -Enolase Deficiency)	115
6.2.7	Glycogen Storage Disease Type XI (Lactate Dehydrogenase Deficiency)	115
6.2.8	Muscle Glycogen Storage Disease Type 0 (Glycogen Synthase Deficiency)	115
6.3	The Generalized Glycogenoses and Related Disorders	115
6.3.1	Glycogen Storage Disease Type II (Acid Maltase Deficiency)	115
6.3.2	Danon Disease	116
6.3.3	Lafora Disease	116
	References	116
7	Disorders of Galactose Metabolism	121
	<i>Gerard T. Berry, Stanton Segal, Richard Gitzelmann</i>	
7.1	Deficiency of Galactose-1-Phosphate Uridyltransferase	123
7.1.1	Clinical Presentation	123
7.1.2	Metabolic Derangement	123
7.1.3	Genetics	123
7.1.4	Diagnostic Tests	124
7.1.5	Treatment and Prognosis	124

7.2	Uridine Diphosphate-Galactose 4'-Epimerase Deficiency	126	9.3.4	Diagnosis	141
7.2.1	Clinical Presentation	126	9.3.5	Differential Diagnosis	141
7.2.2	Metabolic Derangement	126	9.3.6	Treatment and Prognosis	141
7.2.3	Genetics	126		References	142
7.2.4	Diagnostic Tests	127	10	Persistent Hyperinsulinemic Hypoglycemia	143
7.2.5	Treatment and Prognosis	127		<i>Pascale de Lonlay, Jean-Marie Saudubray</i>	
7.3	Galactokinase Deficiency	127	10.1	Clinical Presentation	145
7.3.1	Clinical Presentation	127	10.2	Metabolic Derangement	145
7.3.2	Metabolic Derangement	127	10.3	Genetics	146
7.3.3	Genetics	127	10.4	Diagnostic Tests	146
7.3.4	Diagnostic Tests	127	10.4.1	Diagnostic Criteria	146
7.3.5	Treatment and Prognosis	128	10.4.2	Differentiation of Focal from Diffuse Forms	146
7.4	Fanconi-Bickel Syndrome	128	10.5	Treatment and Prognosis	147
7.5	Portosystemic Venous Shunting and Hepatic Arterio-Venous Malformations	128	10.5.1	Medical Treatment	147
	References	128	10.5.2	Surgical Treatment	147
			10.5.3	Prognosis	147
8	Disorders of the Pentose Phosphate Pathway.	131		References	148
	<i>Nanda M. Verhoeven, Cornelis Jakobs</i>		11	Disorders of Glucose Transport.	151
8.1	Ribose-5-Phosphate Isomerase Deficiency	133		<i>René Santer, Jörg Klepper</i>	
8.1.1	Clinical Presentation	133	11.1	Congenital Glucose/Galactose Malabsorption (SGLT1 Deficiency)	153
8.1.2	Metabolic Derangement	133	11.1.1	Clinical Presentation	153
8.1.3	Genetics	133	11.1.2	Metabolic Derangement	153
8.1.4	Diagnostic Tests	133	11.1.3	Genetics	153
8.1.5	Treatment and Prognosis	133	11.1.4	Diagnosis	153
8.2	Transaldolase Deficiency	133	11.1.5	Treatment and Prognosis	154
8.2.1	Clinical Presentation	133	11.2	Renal Glucosuria (SGLT2 Deficiency)	154
8.2.2	Metabolic Derangement	134	11.2.1	Clinical Presentation	154
8.2.3	Genetics	134	11.2.2	Metabolic Derangement	154
8.2.4	Diagnostic Tests	134	11.2.3	Genetics	154
8.2.5	Treatment and Prognosis	134	11.2.4	Diagnosis	154
	References	134	11.2.5	Treatment and Prognosis	154
9	Disorders of Fructose Metabolism	135	11.3	Glucose Transporter Deficiency Syndrome (GLUT1 Deficiency)	154
	<i>Beat Steinmann, René Santer, Georges van den Berghe</i>		11.3.1	Clinical Presentation	154
9.1	Essential Fructosuria	137	11.3.2	Metabolic Derangement	155
9.1.1	Clinical Presentation	137	11.3.3	Genetics	155
9.1.2	Metabolic Derangement	137	11.3.4	Diagnosis	155
9.1.3	Genetics	137	11.3.5	Treatment and Prognosis	155
9.1.4	Diagnosis	137	11.4	Fanconi-Bickel Syndrome (GLUT2 Deficiency)	155
9.1.5	Treatment and Prognosis	137	11.4.1	Clinical Presentation	155
9.2	Hereditary Fructose Intolerance	137	11.4.2	Metabolic Derangement	156
9.2.1	Clinical Presentation	137	11.4.3	Genetics	156
9.2.2	Metabolic Derangement	138	11.4.4	Diagnosis	156
9.2.3	Genetics	138	11.4.5	Treatment and Prognosis	156
9.2.4	Diagnosis	138		References	157
9.2.5	Differential Diagnosis	139			
9.2.6	Treatment and Prognosis	139			
9.3	Fructose-1,6-Bisphosphatase Deficiency	140			
9.3.1	Clinical Presentation	140			
9.3.2	Metabolic Derangement	140			
9.3.3	Genetics	141			

III Disorders of Mitochondrial Energy Metabolism

12 Disorders of Pyruvate Metabolism and the Tricarboxylic Acid Cycle	161	14.1.3 Succinyl-CoA 3-Oxoacid CoA Transferase Deficiency	193
<i>Linda J. De Meirleir, Rudy Van Coster, Willy Lissens</i>		14.1.4 Mitochondrial Acetoacetyl-CoA Thiolase Deficiency	193
12.1 Pyruvate Carboxylase Deficiency	163	14.2 Metabolic Derangement	194
12.2 Phosphoenolpyruvate Carboxykinase Deficiency	165	14.3 Genetics	194
12.3 Pyruvate Dehydrogenase Complex Deficiency . .	167	14.4 Diagnostic Tests	194
12.4 Dihydrolipoamide Dehydrogenase Deficiency . .	169	14.4.1 Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency	194
12.5 2-Ketoglutarate Dehydrogenase Complex Deficiency	169	14.4.2 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency	194
12.6 Fumarase Deficiency	170	14.4.3 Succinyl-CoA 3-Oxoacid CoA Transferase Deficiency	195
12.7 Succinate Dehydrogenase Deficiency	171	14.4.4 Mitochondrial Acetoacetyl-CoA Thiolase Deficiency	195
12.8 Pyruvate Transporter Defect	172	14.5 Treatment and Prognosis	195
References	172	14.6 Cytosolic Acetoacetyl-CoA Thiolase Deficiency . .	195
		References	196
13 Disorders of Mitochondrial Fatty Acid Oxidation and Related Metabolic Pathways	175	15 Defects of the Respiratory Chain	197
<i>Charles A. Stanley, Michael J. Bennett, Ertan Mayatepek</i>		<i>Arnold Munnich</i>	
13.1 Introduction	177	15.1 Clinical Presentation	199
13.2 Clinical Presentation	177	15.1.1 Fetuses	199
13.2.1 Carnitine Cycle Defects	177	15.1.2 Neonates	199
13.2.2 β -Oxidation Defects	179	15.1.3 Infants	201
13.2.3 Electron Transfer Defects	180	15.1.4 Children and Adults	201
13.2.4 Ketogenesis Defects	180	15.2 Metabolic Derangement	201
13.3 Genetics	180	15.3 Genetics	202
13.4 Diagnostic Tests	181	15.3.1 Mutations in Mitochondrial DNA	203
13.4.1 Disease-Related Metabolites	181	15.3.2 Mutations in Nuclear DNA	203
13.4.2 Tests of Overall Pathway	182	15.3.3 Genetic Analysis of Respiratory Chain Deficiencies	203
13.4.3 Enzyme Assays	183	15.3.4 Genetic Counseling and Prenatal Diagnosis . .	204
13.4.4 Prenatal Diagnosis	183	15.4 Diagnostic Tests	204
13.4.5 Treatment and Prognosis	184	15.4.1 Screening Tests	204
13.5.1 Management of Acute Illness	184	15.4.2 Enzyme Assays	204
13.5.2 Long-term Diet Therapy	184	15.4.3 Histopathological Studies	206
13.5.3 Carnitine Therapy	184	15.4.4 Magnetic Resonance Spectroscopy of Muscle and Brain	207
13.5.4 Other Therapy	184	15.5 Treatment and Prognosis	207
13.5.5 Prognosis	185	References	208
13.6 Rare Related Disorders	187	16 Creatine Deficiency Syndromes	211
13.6.1 Transport Defect of Fatty Acids	187	<i>Sylvia Stöckler-Ipsiroglu, Gajja S. Salomons</i>	
13.6.2 Defects in Leukotriene Metabolism	187	16.1 Clinical Presentation	213
References	188	16.1.1 Guanidinoacetate Methyltransferase Deficiency	213
14 Disorders of Ketogenesis and Ketolysis	191	16.1.2 Arginine:Glycine Amidinotransferase Deficiency	213
<i>Andrew A.M. Morris</i>		16.1.3 SLC6A8 Deficiency	213
14.1 Clinical Presentation	193	16.2 Metabolic Derangement	214
14.1.1 Mitochondrial 3-Hydroxy-3-Methylglutaryl-CoA Synthase Deficiency	193	16.3 Genetics	214
14.1.2 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency	193	16.4 Diagnostic Tests	214
		16.4.1 MRS of Brain	214

16.4.2	Metabolic Screening	214	18.2.3	Genetics	239
16.4.3	DNA Diagnostics	215	18.2.4	Diagnostic Tests	239
16.4.4	Functional Tests/Enzymatic Diagnostics	215	18.2.5	Treatment and Prognosis	239
16.4.5	Prenatal Diagnosis	215	18.3	Hereditary Tyrosinaemia Type III	239
16.5	Treatment and Prognosis	215	18.3.1	Clinical Presentation	239
16.5.1	GAMT Deficiency	215	18.3.2	Metabolic Derangement	239
16.5.2	AGAT Deficiency	216	18.3.3	Genetics	240
16.5.3	SLC6A8 Deficiency	216	18.3.4	Diagnostic Tests	240
	References	216	18.3.5	Treatment and Prognosis	240
			18.4	Transient Tyrosinaemia	240
			18.5	Alkaptonuria	240
			18.5.1	Clinical Presentation	240
			18.5.2	Metabolic Derangement	241
			18.5.3	Genetics	241
			18.5.4	Diagnostic Tests	241
			18.5.5	Treatment and Prognosis	241
			18.6	Hawkinsinuria	241
			18.6.1	Clinical Presentation	241
			18.6.2	Metabolic Derangement	241
			18.6.3	Genetics	241
			18.6.4	Diagnostic Tests	241
			18.6.5	Treatment and Prognosis	242
				References	242
IV	Disorders of Amino Acid Metabolism and Transport		19	Branched-Chain Organic Acidurias/Acidemias	245
17	Hyperphenylalaninaemia	221		<i>Udo Wendel, Hélène Ogier de Baulny</i>	
	<i>John H. Walter, Philip J. Lee, Peter Burgard</i>		19.1	Maple Syrup Urine Disease, Isovaleric Aciduria, Propionic Aciduria, Methylmalonic Aciduria	247
17.1	Introduction	223	19.1.1	Clinical Presentation	247
17.2	Phenylalanine Hydroxylase Deficiency	223	19.1.2	Metabolic Derangement	249
17.2.1	Clinical Presentation	223	19.1.3	Genetics	250
17.2.2	Metabolic Derangement	223	19.1.4	Diagnostic Tests	251
17.2.3	Genetics	223	19.1.5	Treatment and Prognosis	251
17.2.4	Diagnostic Tests	224	19.2	3-Methylcrotonyl Glycinuria	256
17.2.5	Treatment and Prognosis	224	19.2.1	Clinical Presentation	256
17.3	Maternal Phenylketonuria	227	19.2.2	Metabolic Derangement	256
17.3.1	Clinical Presentation	227	19.2.3	Genetics	257
17.3.2	Metabolic Derangement	227	19.2.4	Diagnostic Tests	257
17.3.3	Management	227	19.2.5	Treatment and Prognosis	257
17.3.4	Prognosis	228	19.3	3-Methylglutaconic Aciduria Type I	257
17.4	Hyperphenylalaninaemia and Disorders of Biopterin Metabolism	229	19.4	Short/Branched-Chain Acyl-CoA Dehydrogenase Deficiency	258
17.4.1	Clinical Presentation	229	19.5	2-Methyl-3-Hydroxybutyryl-CoA Dehydrogenase Deficiency	258
17.4.2	Metabolic Derangement	229	19.6	Isobutyryl-CoA Dehydrogenase Deficiency	259
17.4.3	Genetics	229	19.7	3-Hydroxyisobutyric Aciduria	259
17.4.4	Diagnostic Tests	229	19.8	Malonic Aciduria	259
17.4.5	Treatment	230	19.8.1	Clinical Presentation	259
17.4.6	Outcome	230	19.8.2	Metabolic Derangement	259
	References	231	19.8.3	Genetics	259
18	Disorders of Tyrosine Metabolism	233	19.8.4	Diagnostic Tests	260
	<i>Anupam Chakrapani, Elisabeth Holme</i>		19.8.5	Treatment and Prognosis	260
18.1	Hereditary Tyrosinaemia Type I (Hepatorenal Tyrosinaemia)	235		References	260
18.1.1	Clinical Presentation	235			
18.1.2	Metabolic Derangement	235			
18.1.3	Genetics	236			
18.1.4	Diagnostic Tests	236			
18.1.5	Treatment and Prognosis	237			
18.2	Hereditary Tyrosinaemia Type II (Oculocutaneous Tyrosinaemia, Richner-Hanhart Syndrome)	238			
18.2.1	Clinical Presentation	238			
18.2.2	Metabolic Derangement	239			

20	Disorders of the Urea Cycle and Related Enzymes	263	21.5	γ-Cystathionase Deficiency	280
	<i>James V. Leonard</i>		21.5.1	Clinical Presentation	280
20.1	Clinical Presentation	265	21.5.2	Metabolic Derangement	280
20.1.1	Neonatal Presentation	265	21.5.3	Genetics	280
20.1.2	Infantile Presentation	265	21.5.4	Diagnostic Tests	280
20.1.3	Children and Adults	265	21.5.5	Treatment and Prognosis	280
20.2	Metabolic Derangement	266	21.6	Isolated Sulfite Oxidase Deficiency	280
20.2.1	The Urea Cycle	266	21.6.1	Clinical Presentation	280
20.2.2	Toxicity of Ammonia	267	21.6.2	Metabolic Derangement	280
20.3	Genetics	267	21.6.3	Genetics	281
20.4	Diagnostic Tests	268	21.6.4	Diagnostic Tests	281
20.4.1	Biochemical Tests	268	21.6.5	Treatment and Prognosis	281
20.4.2	Imaging	268		References	281
20.4.3	Differential Diagnosis	268	22	Disorders of Ornithine Metabolism	283
20.4.4	Prenatal Diagnosis	269		<i>Vivian E. Shih, Matthias R. Baumgartner</i>	
20.5	Treatment	269	22.1	Hyperornithinemia due to Ornithine Amino-transferase Deficiency (Gyrate Atrophy of the Choroid and Retina)	285
20.5.1	Low-Protein Diet	269	21.1.1	Clinical Presentation	285
20.5.2	Essential Amino Acids	269	22.1.2	Metabolic Derangement	285
20.5.3	Alternative Pathways for Nitrogen Excretion	269	22.1.3	Genetics	286
20.5.4	Replacement of Deficient Nutrients	270	22.1.4	Diagnostic Tests	286
20.5.5	General Aspects of Therapy	270	22.1.5	Treatment and Prognosis	286
20.5.6	Emergency Management at Home	270	22.2	The Hyperornithinemia, Hyperammonemia, and Homocitrullinuria (HHH) Syndrome	288
20.5.7	Emergency Treatment in Hospital	271	21.2.1	Clinical Presentation	288
20.6	Prognosis	272	22.2.2	Metabolic Derangement	288
	References	272	22.2.3	Genetics	288
21	Disorders of Sulfur Amino Acid Metabolism	273	22.2.4	Diagnostic Tests	288
	<i>Generoso Andria, Brian Fowler, Gianfranco Sebastio</i>		22.2.5	Treatment and Prognosis	288
21.1	Homocystinuria due to Cystathione β -Synthase Deficiency	275	22.3	Δ^1 -Pyrroline-5-Carboxylate Synthase Deficiency	289
21.1.1	Clinical Presentation	275	21.3.1	Clinical Presentation	289
21.1.2	Metabolic Derangement	276	22.3.2	Metabolic Derangement	289
21.1.3	Genetics	276	22.3.3	Genetics	289
21.1.4	Diagnostic Tests	277	22.3.4	Diagnostic Tests	289
21.1.5	Treatment and Prognosis	277	22.3.5	Treatment and Prognosis	289
21.2	Methionine S-Adenosyltransferase Deficiency	278		References	290
21.2.1	Clinical Presentation	278	23	Cerebral Organic Acid Disorders and Other Disorders of Lysine Catabolism	293
21.2.2	Metabolic Derangement	278		<i>Georg F. Hoffmann</i>	
21.2.3	Genetics	279	23.1	Introduction	295
21.2.4	Diagnostic Tests	279	23.2	Hyperlysinemia/Saccharopinuria	295
21.2.5	Treatment and Prognosis	279	23.2.1	Clinical Presentation	295
21.3	Glycine N-Methyltransferase Deficiency	279	23.2.2	Metabolic Derangement	295
21.3.1	Clinical Presentation	279	23.2.3	Genetics	296
21.3.2	Metabolic Derangement	279	23.2.4	Diagnostic Tests	296
21.3.3	Genetics	279	23.2.5	Treatment and Prognosis	296
21.3.4	Diagnostic Tests	279	23.3	Hydroxylysinuria	296
21.3.5	Treatment and Prognosis	279	23.4	2-Amino-/2-Oxo-Adipic Aciduria	296
21.4	S-Adenosylhomocysteine Hydrolase Deficiency	279	23.4.1	Clinical Presentation	296
21.4.1	Clinical Presentation	279	23.4.2	Metabolic Derangement	296
21.4.2	Metabolic Derangement	279	23.4.3	Genetics	296
21.4.3	Genetics	280	23.4.4	Diagnostic Tests	296
21.4.4	Diagnostic Tests	280			
21.4.5	Treatment and Prognosis	280			

23.4.5	Treatment and Prognosis	297	26	Transport Defects of Amino Acids at the Cell Membrane: Cystinuria, Lysinuric Protein Intolerance and Hartnup Disorder	321
23.5	Glutaric Aciduria Type I (Glutaryl-CoA Dehydrogenase Deficiency)	297		<i>Kirsti Nääntö-Salonen, Olli G. Simell</i>	
23.5.1	Clinical Presentation	297	26.1	Cystinuria	323
23.5.2	Metabolic Derangement	297	26.1.1	Clinical Presentation	323
23.5.3	Genetics	300	26.1.2	Metabolic Derangement	323
23.5.4	Diagnostic Tests	300	26.1.3	Genetics	323
23.5.5	Treatment and Prognosis	301	26.1.4	Diagnostic Tests	323
23.6	L-2-Hydroxyglutaric Aciduria	302	26.1.5	Treatment and Prognosis	324
23.6.1	Clinical Presentation	302	26.2	Lysinuric Protein Intolerance	324
23.6.2	Metabolic Derangement	303	26.2.1	Clinical Presentation	324
23.6.3	Genetics	303	26.2.2	Metabolic Derangement	325
23.6.4	Diagnostic Tests	303	26.2.3	Genetics	325
23.6.5	Treatment and Prognosis	303	26.2.4	Diagnostic Tests	325
23.7	D-2-Hydroxyglutaric Aciduria	303	26.2.5	Treatment and Prognosis	326
23.7.1	Clinical Presentation	303	26.3	Hartnup Disorder	326
23.7.2	Metabolic Derangement	303	26.3.1	Clinical Presentation	326
23.7.3	Genetics	303	26.3.2	Metabolic Derangement	326
23.7.4	Diagnostic Tests	304	26.3.3	Genetics	327
23.7.5	Treatment and Prognosis	304	26.3.4	Diagnostic Tests	327
23.8	N-Acetylaspartic Aciduria (Canavan Disease)	304	26.3.5	Treatment and Prognosis	327
23.8.1	Clinical Presentation	304		References	327
23.8.2	Metabolic Derangement	304			
23.8.3	Genetics	304			
23.8.4	Diagnostic Tests	304			
23.8.5	Treatment and Prognosis	305			
	References	305			
24	Nonketotic Hyperglycinemia (Glycine Encephalopathy)	307	V	Vitamin-Responsive Disorders	
	<i>Olivier Dulac, Marie-Odile Rolland</i>				
24.1	Clinical Presentation	309	27	Biotin-Responsive Disorders	331
24.1.1	Neonatal NKH	309		<i>Matthias R. Baumgartner, Terttu Suormala</i>	
24.1.2	Late Onset NKH	309	27.1	Clinical Presentation	333
24.2	Metabolic Derangement	310	27.1.1	Holocarboxylase Synthetase Deficiency	333
24.3	Genetics	311	27.1.2	Biotinidase Deficiency	333
24.4	Diagnostic Tests	311	27.1.3	Biotin-Responsive Basal Ganglia Disease	334
24.5	Differential Diagnosis	311	27.2	Metabolic Derangement	334
24.6	Prenatal Diagnosis	312	27.3	Genetics	334
24.7	Treatment	312	27.3.1	Holocarboxylase Synthetase Deficiency	334
	References	312	27.3.2	Biotinidase Deficiency	335
			27.3.3	Biotin-Responsive Basal Ganglia Disease	335
			27.4	Diagnostic Tests	335
			27.4.1	Holocarboxylase Synthetase Deficiency	335
			27.4.2	Biotinidase Deficiency	336
			27.4.3	Acquired Biotin Deficiency	336
			27.4.4	Prenatal Diagnosis	336
			27.5	Treatment and Prognosis	336
			27.5.1	Holocarboxylase Synthetase Deficiency	336
			27.5.2	Biotinidase Deficiency	336
			27.5.3	Biotin-Responsive Basal Ganglia Disease	337
				References	337
25	Disorders of Proline and Serine Metabolism	315			
	<i>Jaak Jaeken</i>				
25.1	Inborn Errors of Proline Metabolism	317			
25.1.1	Proline Oxidase Deficiency (Hyperprolinemia Type I)	317			
25.1.2	Δ^1 -Pyrroline 5-Carboxylate Dehydrogenase Deficiency (Hyperprolinemia Type II)	317			
25.2	Inborn Errors of Serine Metabolism	318			
25.2.1	3-Phosphoglycerate Dehydrogenase Deficiency	318			
25.2.2	Phosphoserine Phosphatase Deficiency	318			
25.2.3	Serine Deficiency with Ichthyosis and Polyneuropathy	318			
	References	319			

28	Disorders of Cobalamin and Folate Transport and Metabolism	341
	<i>David S. Rosenblatt, Brian Fowler</i>	
28.1	Disorders of Absorption and Transport of Cobalamin	343
28.1.1	Hereditary Intrinsic Factor Deficiency	343
28.1.2	Defective Transport of Cobalamin by Enterocytes (Imerslund-Gräsbeck Syndrome)	343
28.1.3	Haptocorrin (R Binder) Deficiency	344
28.1.4	Transcobalamin Deficiency	344
28.2	Disorders of Intracellular Utilization of Cobalamin	345
28.2.1	Combined Deficiencies of Adenosylcobalamin and Methylcobalamin	345
28.2.2	Adenosylcobalamin Deficiency	347
28.2.3	Methylcobalamin Deficiency	348
28.3	Disorders of Absorption and Metabolism of Folate	351
28.3.1	Hereditary Folate Malabsorption	351
28.3.2	Glutamate-Formiminotransferase Deficiency	351
28.3.3	Methylenetetrahydrofolate Reductase Deficiency	352
	References	353

VI Neurotransmitter and Small Peptide Disorders

29	Disorders of Neurotransmission	357
	<i>Jaak Jaeken, Cornelis Jakobs, Peter T. Clayton, Ron A. Wevers</i>	
29.1	Inborn Errors of Gamma Amino Butyric Acid Metabolism	361
29.1.1	Gamma Amino Butyric Acid Transaminase Deficiency	361
29.1.2	Succinic Semialdehyde Dehydrogenase Deficiency	362
29.2	Inborn Defects of Receptors and Transporters of Neurotransmitters	362
29.2.1	Hyperekplexia	362
29.2.2	GABA Receptor Mutation	363
29.2.3	Mitochondrial Glutamate Transport Defect	363
29.3	Inborn Errors of Monoamine Metabolism	365
29.3.1	Tyrosine Hydroxylase Deficiency	365
29.3.2	Aromatic L-Aminoacid Decarboxylase Deficiency	365
29.3.3	Dopamine β -Hydroxylase Deficiency	366
29.3.4	Monoamine Oxidase-A Deficiency	366
29.3.5	Guanosine Triphosphate Cyclohydrolase-I Deficiency	367
29.4	Inborn Disorders Involving Pyridoxine and Pyridoxal Phosphate	369
29.4.1	Pyridoxine-Responsive Epilepsy	369
29.4.2	Pyridox(am)ine 5'-Phosphate Oxidase Deficiency	370
	References	371

30	Disorders in the Metabolism of Glutathione and Imidazole Dipeptides	373
	<i>Ellinor Ristoff, Agne Larsson, Jaak Jaeken</i>	
30.1	Disorders in the Metabolism of Glutathione	375
30.1.1	γ -Glutamylcysteine Synthetase Deficiency	375
30.1.2	Glutathione Synthetase Deficiency	375
30.1.3	γ -Glutamyl Transpeptidase Deficiency	377
30.1.4	5-Oxoprolinase Deficiency	377
30.1.5	Secondary 5-Oxoprolinuria	377
30.2	Disorders of Imidazole Dipeptides	378
30.2.1	Serum Carnosinase Deficiency	378
30.2.2	Homocarnosinosis	378
30.2.3	Prolidase Deficiency	378
	References	379
31	Trimethylaminuria and Dimethylglycine Dehydrogenase Deficiency	381
	<i>Valerie Walker, Ron A. Wevers</i>	
31.1	Trimethylaminuria (Fish Odour Syndrome)	383
31.1.1	Clinical Presentation	383
31.1.2	Metabolic Derangement	383
31.1.3	Genetics	383
31.1.4	Diagnostic Tests	383
31.1.5	Treatment	383
31.2	Dimethylglycine Dehydrogenase Deficiency	384
31.2.1	Clinical Presentation	384
31.2.2	Metabolic Derangement	384
31.2.3	Genetics	384
31.2.4	Diagnostic Tests	384
31.2.5	Treatment	384
	References	384

VII Disorders of Lipid and Bile Acid Metabolism

32	Dyslipidemias	389
	<i>Annabelle Rodriguez-Oquendo, Peter O. Kwiterovich, Jr.</i>	
32.1	Overview of Plasma Lipid and Lipoprotein Metabolism	391
32.1.1	Exogenous Lipoprotein Metabolism	391
32.1.2	Endogenous Lipoprotein Metabolism	392
32.1.3	Reverse Cholesterol Transport and High Density Lipoproteins	393
32.1.4	Lipid Lowering Drugs	394
32.2	Disorders of Exogenous Lipoprotein Metabolism	394
32.2.1	Lipoprotein Lipase Deficiency	394
32.2.2	Apo C-II Deficiency	395
32.3	Disorders of Endogenous Lipoprotein Metabolism	395
32.3.1	Disorders of VLDL Overproduction	396
32.3.2	Disorders of LDL Removal	397

32.4	Disorders of Endogenous and Exogenous Lipoprotein Transport	399	34.4	Cerebrotendinous Xanthomatosis (Sterol 27-Hydroxylase Deficiency)	426
32.4.1	Dysbetalipoproteinemia (Type III Hyperlipoproteinemia)	399	34.5	α -Methylacyl-CoA Racemase Deficiency	427
32.4.2	Hepatic Lipase Deficiency	400	34.6	Oxysterol 7 α -Hydroxylase Deficiency	428
32.5	Disorders of Reduced LDL Cholesterol Levels	400	34.7	Bile Acid Amidation Defect	428
32.5.1	Abetalipoproteinemia	400	34.8	Cholesterol 7 α -Hydroxylase Deficiency	429
32.5.2	Hypobetalipoproteinemia	401	34.9	Disorders of Peroxisome Biogenesis and Peroxisomal β -Oxidation	429
32.5.3	Homozygous Hypobetalipoproteinemia	401		References	429
32.6	Disorders of Reverse Cholesterol Transport	401			
32.6.1	Familial Hypoalphalipoproteinemia	401			
32.6.2	Apolipoprotein A-I Mutations	401			
32.6.3	Tangier Disease	402			
32.6.4	Lecithin-Cholesterol Acyltransferase Deficiency	402			
32.6.5	Cholesteryl Ester Transfer Protein Deficiency	402			
32.6.6	Elevated Lipoprotein (a)	403			
32.7	Guidelines for the Clinical Evaluation and Treatment of Dyslipidemia	403			
32.7.1	Clinical Evaluation	403			
32.7.2	Dietary Treatment, Weight Reduction and Exercise	404			
32.7.3	Goals for Dietary and Hygienic Therapy	405			
32.7.4	Low Density Lipoprotein-Lowering Drugs	406			
32.7.5	Triglyceride Lowering Drugs	407			
32.7.6	Combination Pharmacotherapy	408			
	Abbreviations	408			
	References	408			
33	Disorders of Cholesterol Synthesis	411	35	Disorders of Purine and Pyrimidine Metabolism	433
	<i>Hans R. Waterham, Peter T. Clayton</i>			<i>Georges van den Berghe, M.- Françoise Vincent, Sandrine Marie</i>	
33.1	Mevalonic Aciduria and Hyper-Immunoglobulinaemia-D and Periodic Fever Syndrome (Mevalonate Kinase Deficiency)	413	35.1	Inborn Errors of Purine Metabolism	435
33.2	Smith-Lemli-Opitz Syndrome (7-Dehydrocholesterol Reductase Deficiency)	414	35.1.1	Phosphoribosyl Pyrophosphate Synthetase Superactivity	435
33.3	X-Linked Dominant Chondrodysplasia Punctata 2 or Conradi-Hünermann Syndrome (Sterol Δ^8 - Δ^7 Isomerase Deficiency)	415	35.1.2	Adenylosuccinase Deficiency	436
33.4	CHILD Syndrome (3β -Hydroxysteroid C-4 Dehydrogenase Deficiency)	416	35.1.3	AICA-Ribosiduria	437
33.5	Desmosterolosis (Desmosterol Reductase Deficiency)	417	35.1.4	Muscle AMP Deaminase Deficiency	437
33.6	Lathosterolosis (Sterol Δ^5 -Desaturase Deficiency)	417	35.1.5	Adenosine Deaminase Deficiency	438
33.7	Hypops-Ectopic Calcification-Moth-Eaten (HEM) Skeletal Dysplasia or Greenberg Skeletal Dysplasia (Sterol Δ^{14} -Reductase Deficiency)	418	35.1.6	Adenosine Deaminase Superactivity	439
33.8	Other Disorders	419	35.1.7	Purine Nucleoside Phosphorylase Deficiency	440
	References	419	35.1.8	Xanthine Oxidase Deficiency	440
			35.1.9	Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency	441
34	Disorders of Bile Acid Synthesis	421	35.1.10	Adenine Phosphoribosyltransferase Deficiency	442
	<i>Peter T. Clayton</i>		35.1.11	Deoxyguanosine Kinase Deficiency	442
34.1	Introduction	423	35.2	Inborn Errors of Pyrimidine Metabolism	445
34.2	3β -Hydroxy- Δ^5 -C ₂₇ -Steroid Dehydrogenase Deficiency	423	35.2.1	UMP Synthase Deficiency (Hereditary Orotic Aciduria)	445
34.3	Δ^4 -3-Oxosteroid 5 β -Reductase Deficiency	425	35.2.2	Dihydropyrimidine Dehydrogenase Deficiency	445
			35.2.3	Dihydropyrimidinase Deficiency	446
			35.2.4	Ureidopropionase Deficiency	446
			35.2.5	Pyrimidine 5'-Nucleotidase Deficiency	446
			35.2.6	Cytosolic 5'-Nucleotidase Superactivity	447
			35.2.7	Thymidine Phosphorylase Deficiency	447
			35.2.8	Thymidine Kinase Deficiency	447
				References	447
			36	Disorders of Heme Biosynthesis	451
				<i>Norman G. Egger, Chul Lee, Karl E. Anderson</i>	
			36.1	X-Linked Sideroblastic Anemia	453
			36.2	Classification of Porphyrias	453
			36.3	Diagnosis of Porphyrias	454
			36.4	5-Aminolevulinic Acid Dehydratase Porphyria	454
			36.5	Acute Intermittent Porphyria	455
			36.6	Congenital Erythropoietic Porphyria (Gunther Disease)	458

36.7	Porphyria Cutanea Tarda	459
36.8	Hepatoerythropoietic Porphyria	460
36.9	Hereditary Coproporphyrin and Variegate Porphyria	461
36.10	Erythropoietic Protoporphyrin	462
	References	463

IX Disorders of Metal Transport

37	Disorders in the Transport of Copper, Zinc and Magnesium	467
	<i>Roderick H.J. Houwen</i>	
37.1	Copper	469
37.1.1	Wilson Disease	469
37.1.2	Menkes Disease	471
37.1.3	Other Copper Storage Disorders	472
37.2	Zinc	472
37.2.1	Acrodermatitis Enteropathica	472
37.2.2	Zinc Deficiency in Breastfed Babies	473
37.2.3	Hyperzincemia with Hypercalproctinemia	473
37.2.4	Autosomal Dominant Hyperzincemia Without Symptoms	473
37.3	Magnesium	474
37.3.1	Primary Hypomagnesemia with Secondary Hypocalcemia	474
37.3.2	Hypomagnesemia with Hypercalciuria and Nephrocalcinosis	474
37.3.3	Isolated Dominant Hypomagnesemia	475
37.3.4	Isolated Autosomal Recessive Hypomagnesemia	475
37.3.5	Other Metals	475
	References	475

X Organelle-Related Disorders: Lysosomes, Peroxisomes, and Golgi and Pre-Golgi Systems

38	Disorders of Sphingolipid Metabolism	479
	<i>Marie-Thérèse Vanier</i>	
38.1	Gaucher Disease	481
38.2	Niemann-Pick Disease Type A and B	482
38.3	GM1-Gangliosidosis	484
38.4	GM2-Gangliosidosis	485
38.5	Krabbe Disease	486
38.6	Metachromatic Leukodystrophy	487
38.7	Fabry Disease	489
38.8	Farber Disease	490
38.9	Prosaposin Deficiency	490
38.10	Niemann-Pick Disease Type C	491
	References	492

39	Mucopolysaccharidoses and Oligo- saccharidoses	495
	<i>J. Ed Wraith</i>	
39.1	Clinical Presentation	497
39.1.1	Mucopolysaccharidoses	497
39.1.2	Oligosaccharidoses	505
39.2	Metabolic Derangements	506
39.3	Genetics	506
39.4	Diagnostic Tests	506
39.5	Treatment and Prognosis	506
	References	507

40	Peroxisomal Disorders	509
	<i>Bwee Tien Poll-The, Patrick Aubourg, Ronald J.A. Wanders</i>	
40.1	Clinical Presentation	511
40.1.1	Dysmorphism	511
40.1.2	Neurological Dysfunction	512
40.1.3	Hepatic and Gastrointestinal Disease	512
40.2	Metabolic Derangements	514
40.2.1	Peroxisome Biogenesis	514
40.2.2	Metabolic Functions of Peroxisomes	515
40.2.3	Metabolic Abnormalities in the Different Peroxisomal Disorders	518
40.3	Genetics	519
40.4	Diagnostic Tests	519
40.4.1	Diagnostic Group 1	519
40.4.2	Diagnostic Group 2	519
40.4.3	Diagnostic Group 3	519
40.4.4	Diagnostic Group 4	520
40.4.5	Histological Detection	520
40.4.6	Prenatal Diagnosis	520
40.5	Treatment and Prognosis	520
	References	521

41	Congenital Disorders of Glycosylation	523
	<i>Jaak Jaeken</i>	
41.1	Introduction	525
41.2	Congenital Disorders of Protein N-Glyco- sylation	526
41.2.1	Phosphomannomutase 2 Deficiency (CDG-Ia)	526
41.2.2	Phosphomannose-Isomerase Deficiency (CDG-Ib)	527
41.2.3	Glucosyltransferase I Deficiency (CDG-Ic)	528
41.3	Congenital Disorders of Protein O-Glyco- sylation	528
41.3.1	Hereditary Multiple Exostoses	528
41.3.2	Walker-Warburg Syndrome	529
41.3.3	Muscle-Eye-Brain Disease	529
41.4	Newly Discovered Disorders	529
41.4.1	COG7 Deficiency	529
41.4.2	GM3 Synthase Deficiency	529
	References	530

42	Cystinosis	531
	<i>Michel Broyer</i>	
42.1	Infantile Cystinosis	533
42.1.1	Clinical Presentation	533
42.1.2	Metabolic Derangement	534
42.1.3	Genetics	535
42.1.4	Diagnostic Tests	535
42.1.5	Treatment	535
42.2	Adolescent Cystinosis	536
42.3	Adult Benign Cystinosis	536
	References	536
43	Primary Hyperoxalurias	539
	<i>Pierre Cochat, Marie-Odile Rolland</i>	
43.1	Primary Hyperoxaluria Type 1	541
43.1.1	Clinical Presentation	541
43.1.2	Metabolic Derangement	542
43.1.3	Genetics	542
43.1.4	Diagnosis	542
43.1.5	Treatment and Prognosis	542
43.2	Primary Hyperoxaluria Type 2	545
43.2.1	Clinical Presentation	545
43.2.2	Metabolic Derangement	545
43.2.3	Genetics	545
43.2.4	Diagnosis	545
43.2.5	Treatment and Prognosis	545
43.3	Non-Type 1 Non-Type 2 Primary Hyperoxaluria ..	545
	References	545
	Subject Index	547